The safety and efficacy of Autologous adipose tissue derived mesenchymal stem cell on cirrhotic patients

The safety and efficacy of Autologous adipose tissue derived mesenchymal stem cell on cirrhotic patients - aipose tissue derived mesenchymal stem cell therapy for hepatitis and cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025582

Enrollment

Registered

2017-01-16

Start date

2017-01-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

adipose derived mesenchymal stem cell infusion therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Cirrhosis is proven by CT and clinical status. 2.Over age of 20 years old. 3.the socre more thtan Child-Pugh score 6 4.Obtained informed consent

Exclusion criteria

Exclusion criteria: A.alcoholic patients B.sever heart disease C.pregnant patients D.malignant tumor such as HCC E.uncontrolled infectious disease F.impossible to obtain an informed consent G.The patient who primary investigator judged unsuitable

Design outcomes

Primary

Measure	Time frame
Liver function(Child-pugh score), respiratory function, general status (performance status), Biochemistry data, Coagulation status)	—

Countries

Japan

Contacts

Public ContactTomohiko Akahoshi

Department of disaster and emergency medicine Surgery

tomohiko@surg2.med.kyushu-u.ac.jp0926426223

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026